Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov;34(8):1081-5.
doi: 10.1007/s10571-014-0095-0. Epub 2014 Aug 15.

Current developments in pharmacogenomics of multiple sclerosis

Rebecca J Carlson  1 , J Ronald Doucette, Adil J Nazarali
Affiliations
Review

Current developments in pharmacogenomics of multiple sclerosis

Rebecca J Carlson et al. Cell Mol Neurobiol. 2014 Nov.

Abstract

Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest or any financial gain from the publication of this article.

Figures

Fig. 1
Fig. 1
Schematic figure showing how a presence of a single nucleotide polymorphism (SNP) in the genome could influence treatment response in multiple sclerosis. MS patient A carrying a non-responsive SNP fails to respond to therapy, whereas MS patient B carrying a responsive SNP allele fares better following therapy
See this image and copyright information in PMC

References

    1. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR (2009) Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 18(4):767–778 - PMC - PubMed
    1. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL, Multiple Sclerosis Genetics Group (2003) HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. American Journal of Human Genetics 72(3):710–716 - PMC - PubMed
    1. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D, Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR (2008) Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 65(3):337–344 - PubMed
    1. Cénit MD, Blanco-Kelly F, de las Heras V, Bartolomé M, de la Concha EG, Urcelay E, Arroyo R, Martínez A (2009) Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler 15(8):913–917 - PubMed
    1. Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, Martin R, Montalban X (2009) Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 66(8):972–978 - PubMed

Publication types

LinkOut - more resources